Repligen (NASDAQ:RGEN) Hits New 52-Week High – Should You Buy?

Repligen Corporation (NASDAQ:RGEN) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $198.87 and last traded at $194.09, with a volume of 1567144 shares. The stock had previously closed at $189.68.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Citigroup upgraded shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Evercore reissued an “outperform” rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Wells Fargo & Company upped their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $168.57.

Repligen Stock Down 1.2%

The company has a market capitalization of $10.85 billion, a PE ratio of 263.33, a P/E/G ratio of 3.55 and a beta of 1.05. The stock’s fifty day moving average is $168.59 and its two-hundred day moving average is $140.59. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the business posted $0.26 EPS. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Bank of Nova Scotia purchased a new stake in Repligen during the second quarter valued at about $3,547,000. American Capital Management Inc. purchased a new position in shares of Repligen in the second quarter worth about $49,262,000. Avidity Partners Management LP increased its stake in shares of Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Repligen in the second quarter valued at approximately $655,000. Finally, Moore Capital Management LP bought a new stake in shares of Repligen in the second quarter valued at approximately $5,123,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.